Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 701–800 of 2,576
Age-related diseases as vicious cycles
Belikov, A. V. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.002 · Cited by 90
Anderson, J. J., Holtz, G., Baskin, P. P., Turner, M., Rowe, B. A., Wang, B., Kounnas, M. Z., Lamb, B. T., Barten, D. M., Felsenstein, K. M., et al. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.11.015 · Cited by 102
“Genetic defects in APP typically result in increased production of b-amyloid peptides including Ab1–40 and Ab1–42 [3], while mutations in presenilin 1 and presenilin 2 result in selective increases in Ab1–42 formation [4,5].”
BackgroundQuiroz‐Baez, R., Rojas, E., & Arias, C. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.06.012 · Cited by 103
Locascio, J. J., Fukumoto, H., Yap, L., Bottiglieri, T., Growdon, J. H., Hyman, B. T., & Irizarry, M. C. (2008) · Archives of Neurology · doi:10.1001/archneur.65.6.776 · Cited by 91
“5) [0-73] ADL at blood drawing 43 (23) [6-87] Biochemical data, mean (SD) [range]b A 40 level, pmol/L 51.”
BackgroundAßT Amyloidogenesis: Unique, or Variation on a Systemic Theme
Kisilevsky, R., Fraser, P. E., & Benson, M. D. (1997) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239709082674 · Cited by 106
Clinical, Pathological, and Biochemical Spectrum of Alzheimer Disease Associated With PS-1 Mutations
Lleó, A., Berezovska, O., Growdon, J. H., & Hyman, B. T. (2004) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200403000-00006 · Cited by 104
Martoglio, B., & Golde, T. E. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg303 · Cited by 98
Aβ amyloidosis induces the initial stage of tau accumulation in APPSw mice
Tomidokoro, Y., Ishiguro, K., Harigaya, Y., Matsubara, E., Ikeda, M., Park, J., Yasutake, K., Kawarabayashi, T., Okamoto, K., & Shoji, M. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01767-5 · Cited by 100
Effects of SEL-12 presenilin on LIN-12 localization and function in Caenorhabditis elegans
Levitan, D., & Greenwald, I. (1998) · Development · doi:10.1242/dev.125.18.3599 · Cited by 92
The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases
Singleton, A., & Hardy, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.040 · Cited by 91
Self-citationAge-related changes of Alzheimer’s disease-associated proteins in cynomolgus monkey brains
Kimura, N., Tanemura, K., Nakamura, S.-I., Takashima, A., Ono, F., Sakakibara, I., Ishii, Y., Kyuwa, S., & Yoshikawa, Y. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.012 · Cited by 99
Patil, S. P., Maki, S., Khedkar, S. A., Rigby, A. C., & Chan, C. (2010) · Journal of Natural Products · doi:10.1021/np900633j · Cited by 91
Biological function of Presenilin and its role in AD pathogenesis
Zhang, S., Zhang, M., Cai, F., & Song, W. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-15 · Cited by 91
“Presenilin mutations result in the production of the more hydrophobic Aβ42 either in conditioned medium in vitro assay [67,118] or in APP/PS1 transgenic mice [119].”
BackgroundDifferential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease
Dorfman, V. B., Pasquini, L., Riudavets, M., López-Costa, J. J., Villegas, A., Troncoso, J. C., Lopera, F., Castaño, E. M., & Morelli, L. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.09.016 · Cited by 90
“…pathogenic mutations in APP induce over-expression f A 42 or a mutated isoform of A 40 with increased amyoidogenic properties while mutations in PSEN1/2 proteins lter the normal proteolytic processing of APP resulting n the increase of brain soluble A 42/A 40 peptides ratio Scheuner et al., 1996).”
BackgroundStatins in the Prevention and Treatment of Alzheimer Disease
Crisby, M., Carlson, L. A., & Winblad, B. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200207000-00001 · Cited by 91
“Subtle changes in A 42 levels have been reported to be the likely cause of various forms of hereditary AD due to point mutations in the APP and presenilin genes (Younkin et al., 1995; Scheuner et al., 1996).”
BackgroundBrain Trauma in Aged Transgenic Mice Induces Regression of Established Aβ Deposits
Nakagawa, Y., Reed, L., Nakamura, M., McIntosh, T. K., Smith, D. H., Saatman, K. E., Raghupathi, R., Clemens, J., Saido, T. C., Lee, V. M.-Y., et al. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7375 · Cited by 91
Hu, L., Wong, T. P., Côté, S. L., Bell, K. F. S., & Cuello, A. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00394-4 · Cited by 90
Bahr, B. A., Hoffman, K. B., Yang, A. J., Hess, U. S., Glabe, C. G., & Lynch, G. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980720)397:1<139::aid-cne10>3.0.co;2-k · Cited by 90
Alzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 88
Pin1 in Alzheimer's disease: Multiple substrates, one regulatory mechanism?
Balaštík, M., Lim, J., Pastorino, L., & Lu, K. P. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.01.006 · Cited by 100
Busciglio, J., Hartmann, H., Lorenzo, A., Wong, C., Baumann, K., Sommer, B., Staufenbiel, M., & Yankner, B. A. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-13-05101.1997 · Cited by 69
“…is supported by a recent report, which showed that plasma levels of the highly amyloidogenic 42 amino acid form of Ab are increased in individuals that harbor PS1 mutations, and that cultured fibroblasts from these individuals secrete higher levels of Ab42 than controls (Scheuner et al., 1996).”
BackgroundResultAbramowski, D., Wiederhold, K.-H., Furrer, U., Jaton, A.-L., Neuenschwander, A., Runser, M.-J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140327 · Cited by 89
Liu, Q., Waltz, S., Woodruff, G., Ouyang, J., Israel, M. A., Herrera, C., Sarsoza, F., Tanzi, R. E., Koo, E. H., Ringman, J. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2482 · Cited by 91
Self-citationRyder, J. W., Yuan, S., & Ni, B. (2003) · Cellular Signalling · doi:10.1016/j.cellsig.2003.07.004 · Cited by 107
Apolipoprotein E modulates γ‐secretase cleavage of the amyloid precursor protein
Irizarry, M. C., Deng, A., Lleo, A., Berezovska, O., Von Arnim, C. A. F., Martin‐Rehrmann, M., Manelli, A., LaDu, M. J., Hyman, B. T., & Rebeck, G. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02581.x · Cited by 89
“The ELISAs are well characterized (Asami-Odaka et al. 1995; Scheuner et al. 1996; Kosaka et al. 1997) and are sensitive to 1 pM Ab.”
BackgroundAmtul, Z., Lewis, P. A., Piper, S., Crook, R., Baker, M., Findlay, K., Singleton, A., Hogg, M., Younkin, L., Younkin, S. G., et al. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0473 · Cited by 89
Self-citationMolecular basis of Alzheimer's disease
Drouet, B., Pinçon‐Raymond, M., Chambaz, J., & Pillot, T. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050035 · Cited by 103
Intertwined and Finely Balanced: Endoplasmic Reticulum Morphology, Dynamics, Function, and Diseases
Perkins, H. T., & Allan, V. (2021) · Cells · doi:10.3390/cells10092341 · Cited by 100
“Alzheimer’s Disease Presenilins [331] ER Ca2+ homeostasis [332] Ca 2+ homeostasis dysregulated [333–335]”
BackgroundAmyloid β Levels in Human Red Blood Cells
Kiko, T., Nakagawa, K., Satoh, A., Tsuduki, T., Furukawa, K., Arai, H., & Miyazawa, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049620 · Cited by 107
β‐Amyloid (Aβ)42(43), Aβ42, Aβ40 and apoE immunostaining of plaques in fatal head injury
Horsburgh, K., Cole, G. M., Yang, F., Savage, M. J., Greenberg, B. D., Gentleman, S. M., Graham, D. I., & Nicoll, J. A. R. (2000) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2000.026002124.x · Cited by 88
The missing link in the amyloid cascade of Alzheimer’s disease – Metal ions
Tiiman, A., Palumaa, P., & Tõugu, V. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.023 · Cited by 104
“Therefore it is proposed that Ab42 is more amyloidogenic.”
InfluentialRahimi, F., Shanmugam, A., & Bitan, G. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533358 · Cited by 88
“Although such high A concentrations used to generate amy balls are unlikely to occur in vivo [22, 199], it was argued that these concentrations could possibly occur locally at microfoci circumscribing the amyloid plaques in AD brain [39].”
BackgroundStrack, S., Zaucha, J. A., Ebner, F. F., Colbran, R. J., & Wadzinski, B. E. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980323)392:4<515::aid-cne8>3.0.co;2-3 · Cited by 203
Self-citationThe genetics of late-onset Alzheimerʼs disease
Myers, A. J., & Goate, A. M. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00002 · Cited by 88
Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein
Gómez, W., Morales, R., Maracaja‐Coutinho, V., Parra, V., & Nassif, M. (2020) · Aging · doi:10.18632/aging.102677 · Cited by 103
Manzoni, C., Mamais, A., Dihanich, S., McGoldrick, P., Devine, M. J., Zerle, J., Kara, E., Taanman, J.-W., Healy, D. G., Marti-Masso, J.-F., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.159 · Cited by 81
Self-citationSomatostatin and Alzheimer's disease
Burgos‐Ramos, E., Hervás‐Aguilar, A., Aguado‐Llera, D., Puebla‐Jiménez, L., Hernández‐Pinto, A. M., Barrios, V., & Arilla, E. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.01.014 · Cited by 100
Szczepanik, A. M., Rampe, D., & Ringheim, G. E. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00240.x · Cited by 87
Spike bursts increase amyloid-β 40/42 ratio by inducing a presenilin-1 conformational change
Dolev, I., Fogel, H., Milshtein-Parush, H., Berdichevsky, Y., Lipstein, N., Brose, N., Gazit, N., & Slutsky, I. (2013) · Nature Neuroscience · doi:10.1038/nn.3376 · Cited by 98
Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation
Nilsson, L. N. G., Arendash, G. W., Leighty, R. E., Costa, D. A., Low, M. A., Garcia, M. F., Cracciolo, J. R., Rojiani, A. M., Wu, X., Bales, K. R., et al. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.011 · Cited by 97
“All of the APP and presenilin mutations that have been found to cause familial Alzheimer’s disease with an autosomal dominant mode of inheritance appear to act by increasing the amount of the A 1–42 peptide, which displays a high propensity to polymerize into amyloid filaments [20,57].”
BackgroundAluminum, Alzheimer's disease and bone fragility
Mjöberg, B., Hellquist, E., Mallmin, H., & Lindh, U. (1997) · Acta Orthopaedica Scandinavica · doi:10.3109/17453679708999016 · Cited by 86
Pomara, N., Willoughby, L. M., Sidtis, J. J., & Mehta, P. D. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.10.914 · Cited by 99
β-Secretase Processing of the Alzheimer's Amyloid Protein Precursor (APP)
Marlow, L. A., Cain, M., Pappolla, M. A., & Sambamurti, K. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:233 · Cited by 107
Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility
Theuns, J. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.16.2383 · Cited by 87
Mesquita, S. D., Ferreira, A. C., Gao, F., Coppola, G., Geschwind, D. H., Sousa, J. C., Correia‐Neves, M., Sousa, N., Palha, J. A., & Marques, F. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.06.008 · Cited by 104
“…deposition of amyloid beta (Ab) peptides, in the form of senile plaques, and the formation of intracellular neurofibrillary tangles, as a result of increased aggregation of hyperphosphorylated Tau protein (Gotz et al., 2001; Hardy and Selkoe, 2002; Lewis et al., 2001; Scheuner et al., 1996).”
Serum Creatinine Levels Correlate With Plasma Amyloid β Protein
Arvanitakis, Z., Lucas, J. A., Younkin, L. H., Younkin, S. G., & Graff-Radford, N. R. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200207000-00009 · Cited by 84
“A is a normal, secreted protein that is readily detected in plasma (Scheuner et al., 1996).”
BackgroundMethodSelf-citationMutant Presenilin 2 Transgenic Mice
Sawamura, N., Morishima-Kawashima, M., Waki, H., Kobayashi, K., Kuramochi, T., Frosch, M. P., Ding, K., Ito, M., Kim, T.-W., Tanzi, R. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004308200 · Cited by 87
Self-citationApolipoprotein E, a Gene with Complex Biological Interactions in the Aging Brain
Roses, A. D. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0161 · Cited by 87
Steiner, H., Revesz, T., Neumann, M., Romig, H., Grim, M. G., Pesold, B., Kretzschmar, H. A., Hardy, J., Holton, J. L., Baumeister, R., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007183200 · Cited by 85
Self-citationGenetic factors in Alzheimer's disease: A review of recent advances
Levy‐Lahad, E., & Bird, T. D. (1996) · Annals of Neurology · doi:10.1002/ana.410400604 · Cited by 98
Self-citationAn overview of the genes and biomarkers in Alzheimer’s disease
Krishnamurthy, H. K., Jayaraman, V., Krishna, K., Wang, T., Bei, K., Changalath, C., & Rajasekaran, J. J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102599 · Cited by 98
A transgenic rat model of Alzheimer's disease with extracellular Aβ deposition
Flood, D. G., Lin, Y., Lang, D. M., Trusko, S. P., Hirsch, J. D., Savage, M. J., Scott, R. W., & Howland, D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.10.006 · Cited by 101
The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype
Gérard, H. C., Wildt, K. S., Whittum‐Hudson, J. A., Lai, Z., Ager, J. W., & Hudson, A. P. (2005) · Microbial Pathogenesis · doi:10.1016/j.micpath.2005.05.002 · Cited by 97
Dense‐core and diffuse Aβ plaques in TgCRND8 mice studied with synchrotron FTIR microspectroscopy
Rak, M., Del Bigio, M. R., Mai, S., Westaway, D., & Gough, K. (2007) · Biopolymers · doi:10.1002/bip.20820 · Cited by 87
A review of genome mutation and Alzheimer's disease
Thomas, P., & Fenech, M. F. (2006) · Mutagenesis · doi:10.1093/mutage/gel055 · Cited by 110
Mitochondrial lipids in neurodegeneration
Aufschnaiter, A., Kohler, V., Diessl, J., Peselj, C., Carmona-Gutierrez, D., Keller, W., & Büttner, S. (2017) · Cell and Tissue Research · doi:10.1007/s00441-016-2463-1 · Cited by 83
“While the most prevalent forms are 40 and 42 aa long, mutations in the genes coding for β-secretase and γ-secretase can shift the production towards the 42 aa version (Scheuner et al. 1996).”
BackgroundBejaoui, K., Uchida, Y., Yasuda, S., Ho, M., Nishijima, M., Brown, R. H., Holleran, W. M., & Hanada, K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16450 · Cited by 85
Landman, N., & Kim, T. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.04.001 · Cited by 92
Separation of presenilin function in amyloid β-peptide generation and endoproteolysis of Notch
Kulic, L., Walter, J., Multhaup, G., Teplow, D. B., Baumeister, R., Romig, H., Capell, A., Steiner, H., & Haass, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100049897 · Cited by 85
Ishii, K., Tamaoka, A., Mizusawa, H., Shoji, S.-I., Ohtake, T., Fraser, P. E., Takahashi, H., Tsuji, S., Gearing, M., Mizutani, T., et al. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01363-7 · Cited by 85
Kauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Goate, A. M. (2007) · Annals of Neurology · doi:10.1002/ana.21099 · Cited by 84
Zhu, X., Yu, J., Jiang, T., Wang, P., Cao, L., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8723-8 · Cited by 94
Ubiquitin, Autophagy and Neurodegenerative Diseases
Watanabe, Y., Taguchi, K., & Tanaka, M. (2020) · Cells · doi:10.3390/cells9092022 · Cited by 92
Plasma amyloid β protein is elevated in late-onset Alzheimer disease families
Ertekin-Taner, N., Younkin, L. H., Yager, D. M., Parfitt, F., Baker, M. C., Asthana, S., Hutton, M. L., Younkin, S. G., & Graff-Radford, N. R. (2008) · Neurology · doi:10.1212/01.wnl.0000278386.00035.21 · Cited by 85
Self-citationChen, W., Gamache, E., Rosenman, D. J., Xie, J., Lopez, M. M., Li, Y.-M., & Wang, C. (2014) · Nature Communications · doi:10.1038/ncomms4037 · Cited by 83
Endogenous Presenilin-1 Targets to Endocytic Rather Than Biosynthetic Compartments
Lah, J. J., & Levey, A. I. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0861 · Cited by 84
Olariu, A., Tran, M. H., Yamada, K., Mizuno, M., Hefco, V., & Nabeshima, T. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170025 · Cited by 92
“and neuropsychiatric disorders such as agitation, apathy and an increased anxiety (Hardy et al., 1992; Selkoe, 1996; Scheuner et al., 1996; Weiner et al., 1997).”
Nitsch, R. M., Deng, A., Wurtman, R. J., & Growdon, J. H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69020704.x · Cited by 85
“Furthermore, mutations of the presenilin 1 gene that cause some forms of early-onset familial AD are associated with increased formation of longer Aß peptides in blood, fibroblasts (Scheuner et al., 1996), and brain (Mann et al., 1996).”
BackgroundThe role of APOE polymorphisms in late-onset dementias
Corder, E. H., Lannfelt, L., Bogdanović, N., Fratiglioni, L., & Mori, H. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050223 · Cited by 91
Self-citationThe Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview
Swerdlow, R. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221286 · Cited by 93
Generation of C‐terminally truncated amyloid‐β peptides is dependent on γ‐secretase activity
Beher, D., Wrigley, J. D. J., Owens, A. P., & Shearman, M. S. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00985.x · Cited by 83
“A common mechanism of all these mutations seems to be an elevation of the levels of a 42 amino acid Ab species [Ab(1–42)] in comparison with the shorter species Ab(1–40) (Suzuki et al. 1994; Scheuner et al. 1996).”
Backgroundγ-Secretase as a Target for Alzheimer’s Disease
Wolfe, M. S. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00004-0 · Cited by 96
Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease
Wu, Z., Ciallella, J. R., Flood, D. G., O’Kane, T. M., Bozyczko‐Coyne, D., & Savage, M. J. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.010 · Cited by 96
γ-Secretase Catalyzes Sequential Cleavages of the AβPP Transmembrane Domain
Xu, X. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0957 · Cited by 84
“Shortly after their identification, it was found that the missense mutations in these two genes are associated with increased levels of the long and more aggregation-prone Aβ42, suggesting that these mutations cause disease by altering AβPP processing, especially the formation of the C-termini of Aβ [45,46].”
Receptor-Mediated Transport of Human Amyloid β-Protein 1–40 and 1–42 at the Blood–Brain Barrier
Poduslo, J. F., Curran, G. L., Sanyal, B., & Selkoe, D. J. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0238 · Cited by 83
“…(Haass et al., 1992) and is found in the CSF and plasma of both normal individuals and AD patients (Shoji et al., 1992; Seubert et al., 1992; Scheuner et al., 1996), the source of Ab that contributes to this deposition needs to be identified to facilitate our understanding of the molecular…”
BackgroundSelf-citationMattson, M. P., Lee, J., & Chan, S. L. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:1:29 · Cited by 90
“To further assess the effects of the PS1 mutation on microglial activation we determined levels of inducible nitric oxide synthase (iNOS) an enzyme upregulated in activated microglia ( Possel et al., 2000 ), in hippocampal and cortical tissues from wildtype and PS1mutKI mice that had been treated for 6 h with either s…”
BackgroundMethodFaraone, S. V., Biederman, J., Mennin, D., & Russell, R. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980207)81:1<108::aid-ajmg18>3.0.co;2-n · Cited by 67
Superoxide free radical and intracellular calcium mediate Aβ1–42 induced endothelial toxicity
Suo, Z., Fang, C., Crawford, F., & Mullan, M. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00383-1 · Cited by 92
Guo, Y., Livne‐Bar, I., Zhou, L., & Boulianne, G. L. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-19-08435.1999 · Cited by 89
“A role for presenilin in protein processing or trafficking has been suggested previously on the basis of its subcellular localization (Kovacks et al., 1996; Walter et al., 1996; De Strooper et al., 1997) and its ability to affect the processing of APP in vertebrates (Borchelt et al., 1996; Duff et al., 1996; Scheuner…”
BackgroundAlzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta
Kauwe, J. S. K., Wang, J., Mayo, K., Morris, J. C., Fagan, A. M., Holtzman, D. M., & Goate, A. M. (2009) · neurogenetics · doi:10.1007/s10048-008-0150-4 · Cited by 82
C-Terminal Turn Stability Determines Assembly Differences between Aβ40 and Aβ42
Roychaudhuri, R., Yang, M., Deshpande, A. M., Cole, G. M., Frautschy, S. A., Lomakin, A., Benedek, G. B., & Teplow, D. B. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.11.006 · Cited by 93
“An increase in the absolute amount of Aβ42, or in the Aβ42/Aβ40 concentration ratio, is associated with familial forms of AD.(8,9) In humans, reduction of Aβ42 concentration correlates with a decreased risk for AD.”
BackgroundDifferential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease
Kulstad, J. J., Green, P. S., Cook, D. G., Watson, G. S., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Rhoads, K., Mehta, P. D., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000216274.58185.09 · Cited by 82
Itakura, M., Nakajima, H., Kubo, T., Semi, Y., Kume, S., Higashida, S., Kaneshige, A., Kuwamura, M., Harada, N., Kita, A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.669291 · Cited by 83
“A is produced by endoproteolysis of parental amyloid precursor protein and is secreted into the extracellular space (26).”
BackgroundMuratore, C. R., Zhou, C., Liao, M., Fernandez, M. A., Taylor, W. M., Lagomarsino, V. N., Pearse, R. V., Rice, H. C., Negri, J. M., He, A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.015 · Cited by 85
Self-citationIntramembrane proteolysis by presenilin and presenilin-like proteases
Xia, W., & Wolfe, M. S. (2003) · Journal of Cell Science · doi:10.1242/jcs.00651 · Cited by 82
“, 1997), and in the plasma of mutant gene carriers (Scheuner et al., 1996).”
Westlund, B., Parry, D., Clover, R., Basson, M., & Johnson, C. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2497 · Cited by 82
New therapeutic targets in Alzheimer's disease: brain deregulation of calcium and zinc
Corona, C., Pensalfini, A., Frazzini, V, & Sensi, S. L. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.57 · Cited by 80
Proteomics in animal models of Alzheimer's and Parkinson's diseases
Robinson, R. A. S., Owen, J. B., & Butterfield, D. A. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.07.003 · Cited by 85
“It is widely accepted that the presenilins are a part of the g-secretase complex (Scheuner et al., 1996) and mutations in the transmembrane domain lead to aberrant APP processing.”
BackgroundClusterin levels are increased in Alzheimer's disease and influence the regional distribution of A β
Miners, J. S., Clarke, P., & Love, S. (2017) · Brain Pathology · doi:10.1111/bpa.12392 · Cited by 81
“Most mutations in familial AD are associated with increased amyloidogenic processing of APP and elevated Aβ42 or an increase in the Aβ42:Aβ40 ratio (5-8).”
BackgroundDiez, M., Koıstınaho, J., Kahn, K., Games, D., & Hökfelt, T. G. M. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00261-x · Cited by 89
Non-steroidal Anti-inflammatory Drugs Stimulate Secretion of Non-amyloidogenic Precursor Protein
Avramovich, Y., Amit, T., & Youdim, M. B. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201308200 · Cited by 81
Bejaoui, K., Uchida, Y., Yasuda, S., Ho, M., Nishijima, M., Brown, R. H., Holleran, W. M., & Hanada, K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216450 · Cited by 81
Alzheimer's Disease and Amyloid: Culprit or Coincidence?
Skaper, S. D. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00011-9 · Cited by 91
“The association of mutations in the PS-1 and PS-2 genes with increased Ab42 production and familial forms of AD (Scheuner et al., 1996; Sherrington et al., 1995) provided a basis for the generation of APP and presenilin double transgenic mice (Borchelt et al., 1997; Holcomb et al., 1998; Richards…”
BackgroundHock, C., Golombowski, S., Müller-Spahn, F., Naser, W., Beyreuther, K., Mönning, U., Schenk, D., Vigo-Pelfrey, C., Bush, A. M., Moir, R., et al. (1998) · European Neurology · doi:10.1159/000007917 · Cited by 81
Self-citationPrice, J. M., Chi, X., Hellermann, G., & Sutton, E. T. (2001) · Neurological Research · doi:10.1179/016164101101198758 · Cited by 80
Wang, Y., Yin, H., Wang, L., Shuboy, A., Lou, J., Han, B., Zhang, X., & Li, J. (2013) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x13500055 · Cited by 80
Fan, D., Liu, L., Wu, Z., & Cao, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180419141613 · Cited by 85
Processing of Amyloid Precursor Protein in Human Primary Neuron and Astrocyte Cultures
LeBlanc, A. C., Papadopoulos, M., Bélair, C., Chu, W., Crosato, M., Powell, J., & Goodyer, C. G. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68031183.x · Cited by 74
Skovronsky, D. M., Fath, S., Lee, V. M. ‐., & Milla, M. E. (2001) · Journal of Neurobiology · doi:10.1002/neu.1064 · Cited by 80
Ertekin-Taner, N. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg343 · Cited by 82
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.